Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study

BACKGROUND: The multikinase inhibitors (MKIs) sorafenib, lenvatinib, and vandetanib are approved for advanced thyroid cancer (TC) in Japan. How sequential treatment with MKIs is conducted in Japanese clinical practice is unknown. METHODS: This retrospective observational cohort study used a Japanese...

Descripción completa

Detalles Bibliográficos
Autores principales: Masaki, Chie, Sugino, Kiminori, Tanizawa, Yoshinori, Nakamura, Kenichi, Okada, Yui, Cai, Zhihong, Okamoto, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943803/
https://www.ncbi.nlm.nih.gov/pubmed/36527599
http://dx.doi.org/10.1007/s40801-022-00346-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943803/
https://www.ncbi.nlm.nih.gov/pubmed/36527599
http://dx.doi.org/10.1007/s40801-022-00346-y

Ejemplares similares